Private Sector Investing More Than Previously Thought In Efforts To Address Antimicrobial Resistance, Report Shows

Devex: Funding outlook shifts in fight against antimicrobial resistance
“Twenty-two research-based biopharmaceutical companies — including AstraZeneca, GlaxoSmithKline, and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR…” (Anders, 1/18).